logo

For the Inventor, By the Inventor

Suwon, South Korea

Hyun Ho Choi

This inventor holds 71 USPTO granted patents and 11 published patent applications and 17 EPO patents, primarily in Pharmaceutical Compositions (CPC class C07D). Top assignees: Samsung Electronics Co., Ltd., Korea Advanced Institute of Science and Technology, Yuhan Corporation. Active years: 2011-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hyun Ho Choi. Retrieved from https://idiyas.com/inventor/hyun-ho-choi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 71 

% Patents Active = 91.5

 

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 124(Granted Patents)

Forward Citations (Not Self Cited) = 101(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Daejeon, KR (2012 - 2014)
  • Suwon-si, JP (2014)
  • Gyeonggi-do, KR (2011 - 2015)
  • Suwon, KR (2013 - 2017)
  • Yongin-si, KR (2012 - 2022)
  • Suwon-si, KR (2011 - 2023)

Company Filing History:

goldMedal59 out of 132,108 
 
Samsung Electronics Co., Ltd.
 patents
silverMedal15 out of 2,790 
 
Korea Advanced Institute of Science and Technology
 patents
bronzeMedal12 out of 97 
 
Yuhan Corporation
 patents
4. 2 out of 7,633 
 
Samsung Electro-Mechanics Co., Ltd.
 patents
5. 1 out of 549 
 
Snu Rdb Foundation
 patents
6. 1 out of 1,357 
 
Sungkyunkwan University
 patents
where one patent can have more than one assignee

Years Active: 2011-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Triazolopyridin-3-ones
Triazolone Derivatives
FGF21 Fusion Proteins
Hepatitis Treatment
Semiconductor Processing
Interference Control
Cognitive Radio
Wireless Communication
Multi-Cell Networks
Data Transmission
Error Correction Codes
71 patents (USPTO):Explore Patents
1. 11820769 - Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same (2023-11-21),
2. 11780830 - Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same (2023-10-10),
3. 11713308 - 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same (2023-08-01),
4. 11527427 - Semiconductor processing apparatus and semiconductor processing system (2022-12-13),
5. 11492335 - Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same (2022-11-08),
6. 11179440 - Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis (2021-11-23),
7. 11168073 - 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same (2021-11-09),
8. 11142557 - Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same (2021-10-12),
9. 11136364 - Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same (2021-10-05),
10. 11091479 - Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same (2021-08-17),
11. 10995086 - Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same (2021-05-04),
12. 10899719 - Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same (2021-01-26),
13. 10562865 - Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same (2020-02-18),
14. 9571177 - Communication method of macro base station, macro terminal, micro base station, and micro terminal for interference control in hierarchical cellular network (2017-02-14),
15. 9445423 - Communication method of a base station and a terminal (2016-09-13),

Sure, here is the article:

Title: Hyun Ho Choi: A Trailblazer in Innovation and Technology

Introduction:

Hyun Ho Choi, a distinguished inventor based in Suwon-si, South Korea, has left an indelible mark in the realm of innovation with his remarkable achievements. With a staggering 71 patents to his name, Choi is a true visionary with a penchant for pushing the boundaries of what is achievable in the technology sector.

Latest Patents:

Choi's latest patents include groundbreaking technologies such as Triazolopyridin-3-ones and Triazolone derivatives, which have significant implications in the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH). These inventions highlight Choi's expertise in developing novel pharmaceutical compositions with a focus on VAP-1 inhibitory activity.

Career Highlights:

Throughout his illustrious career, Hyun Ho Choi has made significant contributions to renowned companies such as Samsung Electronics Co., Ltd. and the Korea Advanced Institute of Science and Technology. His innovative spirit and dedication to excellence have propelled him to the forefront of technological advancement, earning him a reputation as a trailblazer in the industry.

Collaborations:

Choi's collaborative work with esteemed colleagues such as Kyung Hun Jang and Hyo Sun Hwang has further enhanced his innovative capabilities. Through synergistic teamwork and shared expertise, Choi and his coworkers have been able to bring cutting-edge technologies to the forefront of the market, solidifying their position as leaders in the field.

Conclusion:

In conclusion, Hyun Ho Choi stands as a true pioneer in the world of innovation, with a track record of success that speaks for itself. His relentless pursuit of excellence and passion for pushing the boundaries of what is possible make him a force to be reckoned with in the world of technology. Choi's groundbreaking inventions have not only revolutionized the field of pharmaceuticals but have also paved the way for future advancements in the industry. It is clear that Hyun Ho Choi's contributions will continue to shape the landscape of innovation for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…